Volatile oil from Saussurea lappa exerts antitumor efficacy by inhibiting epithelial growth factor receptor tyrosine kinase-mediated signaling pathway in hepatocellular carcinoma

被引：14

作者：

Lin, Xuejing ^{[1
,2
]}

Peng, Zhangxiao ^{[1
,2
]}

Fu, Xiaohui ^{[3
]}

Liu, Chunying ^{[1
,2
]}

Xu, Yang ^{[1
,2
]}

Ji, Weidan ^{[1
,2
]}

Fan, Jianhui ^{[1
,2
]}

Chen, Lei ^{[1
,2
]}

Fang, Lin ^{[4
]}

Huang, Yao ^{[3
]}

Su, Changqing ^{[1
,2
,4
]}

机构：

[1] Second Mil Med Univ, Dept Mol Oncol, Eastern Hepatobiliary Surg Hosp, Shanghai 200438, Peoples R China

[2] Second Mil Med Univ, Natl Ctr Liver Canc, Shanghai 200438, Peoples R China

[3] Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Biliary Tract Surg, Shanghai 200438, Peoples R China

[4] Xuzhou Med Coll, Jiangsu Ctr Collaborat & Innovat Canc Biotherapy, Xuzhou 221002, Peoples R China

来源：

ONCOTARGET | 2016年 / 7卷 / 48期

基金：

中国国家自然科学基金;

关键词：

VOSL; hepatocellular carcinoma; epithelial growth factor receptor; signaling; xenograft model; MATRIX METALLOPROTEINASES; GENE-EXPRESSION; CANCER; COMPOUND; CELLS; EGFR;

D O I：

10.18632/oncotarget.12962

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Hepatocellular carcinoma (HCC) treatment remains lack of effective chemotherapeutic drugs, therefore, discovering novel anti-HCC drugs is a very attractive and urgent task. In this study, we reported VOSL (volatile oil from Saussurea lappa root) exhibits potent therapeutic effect on SMMC-7721 xenografts without obvious side effects. In the in vitro experiments, VOSL inhibited HCC cell proliferation by arresting cell cycle at S and G2/M phases, and induced HCC cell apoptosis by activating the Caspase3 pathway. VOSL also decreased the capability of HCC cell migration and invasion through MMP- 9 depression. Moreover, mechanistic study indicated that VOSL can act as an epithelial growth factor receptor (EGFR) inhibitor to suppress EGFR activation and then to suppress its downstream MEK/P38 and PI3-K/Akt pathways. These results suggested that VOSL may be a novel anti-HCC drug candidate.

引用

页码：79747 / 79759

页数：13

共 36 条

[1] Cross-talk between MET and EGFR in non-small cell lung cancer involves miR-27a and Sprouty2 [J].